Eiko Lifescience

{
  "main_header": {
    "sid": 1002696,
    "name": "Eiko Lifescience",
    "stock_name": "Eiko Lifescience",
    "full_name": "Eiko Lifesciences Ltd",
    "name_url": "stocks-analysis/eiko-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "51.98",
    "chg": 3.19,
    "chgp": "6.54%",
    "dir": 1,
    "prev_price": "48.79",
    "mcapval": "75.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540204,
    "symbol": "",
    "ind_name": "Specialty Chemicals",
    "ind_code": 5,
    "indexname": "India SENSEX",
    "isin": "INE666Q01016",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "7.62 k",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eiko-lifescience-1002696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3893350",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EikoLifescience_mojoScore_3893350.png",
        "date": "2026-03-16 10:10:02",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date insight into the company's performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-by-marketsmojo-3869040",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EikoLifescience_mojoScore_3869040.png",
        "date": "2026-03-04 10:10:02",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3842357",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_mojoScore_3842357.png",
        "date": "2026-02-16 10:10:04",
        "description": "Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3817799",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_mojoScore_3817799.png",
        "date": "2026-02-03 10:14:03",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3813786",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_valuationdot_3813786.png",
        "date": "2026-02-01 08:06:00",
        "description": "Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has witnessed a notable improvement in its valuation attractiveness, shifting from very attractive to attractive. Despite a mixed performance against benchmark indices, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point for investors, even as its overall market sentiment remains cautious with a recent downgrade to a Sell rating."
      },
      {
        "title": "Why is Eiko Lifesciences Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifesciences-ltd-fallingrising-3812260",
        "imagepath": "",
        "date": "2026-01-31 00:55:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Eiko Lifesciences has demonstrated notable resilience and strength in the short term, outperforming the broader market and its sector peers. Over the past week, the stock has delivered a remarkable 10.39% gain, substantially outpacing the Sensex’s modest 0.90% rise during the same period. This outperformance is particularly striking given the Sensex’s negative returns over the past month and year-to-date, which stand at -2.84% and -3.46% respectively. While the stock’s one-year return of 2.45% trails the Sensex’s 7.18%, its recent momentum signals renewed investor confidence.</p>\n<p><strong>Technical Indicators and Trading Activity</strong></p>\n<p>The stock’s technical positioning is robust, trading above all key moving averages inc..."
      },
      {
        "title": "Are Eiko Lifesciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-eiko-lifesciences-ltd-latest-results-good-or-bad-3810120",
        "imagepath": "",
        "date": "2026-01-29 19:24:35",
        "description": "Eiko Lifesciences Ltd's latest financial results for Q2 FY26 reflect a significant year-on-year growth in both net sales and net profit, indicating a robust operational performance. The company reported net sales of ₹11.67 crores, which represents a 43.01% increase compared to ₹8.16 crores in the same quarter last year. This growth is complemented by a substantial rise in net profit, which reached ₹1.08 crores, marking a remarkable 285.71% increase year-on-year. Additionally, the operating margin improved significantly to 15.17%, up from 5.15% in the previous year, showcasing enhanced operational efficiency.\n\nHowever, despite these positive metrics, the company faces challenges regarding its long-term financial health. The average return on equity (ROE) stands at a low 2.71%, raising concerns about capital efficiency and shareholder value creation. This weak ROE is notably below industry standards, suggesti..."
      },
      {
        "title": "Eiko Lifesciences Q2 FY26: Strong Profit Growth Masks Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/eiko-lifesciences-q2-fy26-strong-profit-growth-masks-structural-concerns-3809953",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/EikoLifescience_quaterlyResult_3809953.png",
        "date": "2026-01-29 16:05:01",
        "description": "Eiko Lifesciences Ltd., a micro-cap speciality chemicals manufacturer, reported consolidated net profit of ₹1.08 crores for Q2 FY26, marking an impressive 285.71% year-on-year surge from ₹0.28 crores in Q2 FY25. However, despite the strong earnings momentum, the stock continues to languish, trading at ₹51.01 with a market capitalisation of just ₹71.00 crores, reflecting persistent investor scepticism about the company's long-term sustainability."
      },
      {
        "title": "Eiko Lifesciences Declines 9.99%: Bearish Signals and Downgrade Mark a Challenging Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-declines-999-bearish-signals-and-downgrade-mark-a-challenging-week-3803314",
        "imagepath": "",
        "date": "2026-01-24 13:04:16",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 21:</strong> Formation of Death Cross signalling potential bearish trend</p>\n                    <p><strong>Jan 21:</strong> Downgrade to Sell rating by MarketsMOJO</p>\n                    <p><strong>Jan 23:</strong> Week closes at Rs.49.28 (-9.99%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.53.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.49.28</div><div class=\"stat-change negative\">-9.99%</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\"..."
      }
    ],
    "total": 479,
    "sid": "1002696",
    "stock_news_url": "https://www.marketsmojo.com/news/eiko-lifesciences-1002696"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
      "datetime": "26-Feb-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Bhavesh Dhirajlal Tanna",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "26-Feb-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Lenus Finvest Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "24-Feb-2026",
      "details": "Allotment of 625000 Equity Shares and 2950000 Warrants on preferential basis under SEBI (ICDR) Regulations 2018 through Circulation on Tuesday 24th February 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has declared <strong>2%</strong> dividend, ex-date: 20 Sep 17",
          "dt": "2017-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has announced <strong>2:3</strong> rights issue, ex-date: 07 Jul 23",
          "dt": "2023-07-07",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Eiko Lifesciences Ltd is Rated Sell

2026-03-16 10:10:02

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date insight into the company's performance and outlook.

Read full news article

Eiko Lifesciences Ltd is Rated Sell by MarketsMOJO

2026-03-04 10:10:02

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Eiko Lifesciences Ltd is Rated Sell

2026-02-16 10:10:04

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Eiko Lifesciences Ltd is Rated Sell

2026-02-03 10:14:03

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Eiko Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-02-01 08:06:00

Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has witnessed a notable improvement in its valuation attractiveness, shifting from very attractive to attractive. Despite a mixed performance against benchmark indices, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point for investors, even as its overall market sentiment remains cautious with a recent downgrade to a Sell rating.

Read full news article

Why is Eiko Lifesciences Ltd falling/rising?

2026-01-31 00:55:24

Recent Price Performance and Market Context

Eiko Lifesciences has demonstrated notable resilience and strength in the short term, outperforming the broader market and its sector peers. Over the past week, the stock has delivered a remarkable 10.39% gain, substantially outpacing the Sensex’s modest 0.90% rise during the same period. This outperformance is particularly striking given the Sensex’s negative returns over the past month and year-to-date, which stand at -2.84% and -3.46% respectively. While the stock’s one-year return of 2.45% trails the Sensex’s 7.18%, its recent momentum signals renewed investor confidence.

Technical Indicators and Trading Activity

The stock’s technical positioning is robust, trading above all key moving averages inc...

Read full news article

Are Eiko Lifesciences Ltd latest results good or bad?

2026-01-29 19:24:35

Eiko Lifesciences Ltd's latest financial results for Q2 FY26 reflect a significant year-on-year growth in both net sales and net profit, indicating a robust operational performance. The company reported net sales of ₹11.67 crores, which represents a 43.01% increase compared to ₹8.16 crores in the same quarter last year. This growth is complemented by a substantial rise in net profit, which reached ₹1.08 crores, marking a remarkable 285.71% increase year-on-year. Additionally, the operating margin improved significantly to 15.17%, up from 5.15% in the previous year, showcasing enhanced operational efficiency. However, despite these positive metrics, the company faces challenges regarding its long-term financial health. The average return on equity (ROE) stands at a low 2.71%, raising concerns about capital efficiency and shareholder value creation. This weak ROE is notably below industry standards, suggesti...

Read full news article

Eiko Lifesciences Q2 FY26: Strong Profit Growth Masks Structural Concerns

2026-01-29 16:05:01

Eiko Lifesciences Ltd., a micro-cap speciality chemicals manufacturer, reported consolidated net profit of ₹1.08 crores for Q2 FY26, marking an impressive 285.71% year-on-year surge from ₹0.28 crores in Q2 FY25. However, despite the strong earnings momentum, the stock continues to languish, trading at ₹51.01 with a market capitalisation of just ₹71.00 crores, reflecting persistent investor scepticism about the company's long-term sustainability.

Read full news article

Eiko Lifesciences Declines 9.99%: Bearish Signals and Downgrade Mark a Challenging Week

2026-01-24 13:04:16

Key Events This Week

Jan 21: Formation of Death Cross signalling potential bearish trend

Jan 21: Downgrade to Sell rating by MarketsMOJO

Jan 23: Week closes at Rs.49.28 (-9.99%)

Week Open

Rs.53.00

Week Close

Rs.49.28

-9.99%

Read full news article

View All News